openPR Logo
Press release

Clariant further expands operating margin

05-06-2011 09:56 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Clariant International Ltd

/ PR Agency: EMG
• Sales up 5% in local currencies on price increases, down 6% in CHF
• EBITDA margin before exceptional items at 16.1% compared to 12.9% in the previous year
• EBIT margin before exceptional items rose to 13.4% from 10.1% in Q1 2010
• Positive cash flow from operations of CHF 17 million
• Net income of CHF 120 million compared to CHF 10 million a year ago
• Süd-Chemie acquisition closed, integration process initiated; consolidation
as of 21 April 2011
• 2011 outlook: Clariant expects a stable business environment in 2011, with growth mainly coming from the emerging markets. Based on this scenario and excluding Süd-Chemie, Clariant forecasts local currency sales growth in the low single-digit range and an EBITDA margin before exceptional items above that of 2010.

CEO Hariolf Kottmann commented: “Clariant had a good start to 2011 with a strong performance across the portfolio. Our ongoing focus on delivering a sustainably better performance in the current businesses showed the expected results. By adding the recently acquired Süd-Chemie activities to our portfolio, Clariant will gain access to attractive new markets and to a strong R&D organization focusing on market segments with significant future growth potential. While continuing to manage our businesses for higher margins, the Süd-Chemie portfolio activities will speed up the execution of our profitable growth strategy.”

Clariant Q1 2011 Performance

Muttenz, 6 May 2011 – Clariant, a world leader in specialty chemicals, today announced sales of CHF 1.717 billion for the first quarter of 2011 compared to CHF 1.817 billion in the previous-year period. Sales growth in local currencies amounted to 5%. Due to the appreciation of the Swiss franc against most major currencies, sales were 6% lower in Swiss francs year-on-year.

Overall trading conditions remained stable during the quarter with no restocking activities observed as in the first quarter of 2010. At the regional level, sales growth was quite uniform across all regions with growth rates of between 4% and 7%. The impact from both the disastrous earthquake in Japan and the unrest in North Africa on the business was minimal so far.

In the first quarter, Clariant continued to consistently implement its profitable growth strategy. As a result of the focus on margin management, sales prices improved 5% year-on-year. While not fully compensating for higher raw material costs yet, sales prices increased 2% sequentially with dynamics picking up towards the end of the quarter. This successful price management, lower production costs and a high capacity utilization drove the gross margin up to 29.8% from 28.7% in the same period a year ago.

Clariant further benefited from the positive impact of the implementation of its 2009/10 cost reduction initiatives. Selling, general & administrative (SG&A) costs as a percentage of sales decreased substantially to 15.0% from 16.9% in comparison to the prior-year period. The structurally lower cost base supported the margin development. As a consequence of a better gross margin and lower costs, the EBITDA before exceptional items increased to CHF 277 million, compared to CHF 235 million one year ago. The corresponding margin rose to 16.1% from 12.9% in the previous-year period. The operating profit (EBIT) margin before exceptional items improved to 13.4% from 10.1% in the same period one year ago.

The EBITDA and EBIT margins after restructuring improved to 15.1% from 7.4% and to 11.7% from 4.1% respectively, illustrating the lower restructuring and impairment expenses after completion of the 2009/10 restructuring phase.

Cash flow from operations stood at CHF 17 million, considerably lower than the CHF 159 million achieved in the previous year. After an overly tight management of working capital towards the end of 2010, inventories returned to more normalized levels, therefore negatively impacting the cash flow from operations in Q1.

Net debt increased to CHF 250 million from CHF 126 million, resulting in a gearing (net debt divided by equity) of 13% at the end of the first quarter of 2011, slightly higher than the 7% recorded at the end of 2010.

Update on Süd-Chemie acquisition

On 21 April, Clariant completed the purchase of 96.15% of the shares in Süd-Chemie from One Equity Partners and the family shareholders. The overall transaction value amounted to approximately EUR 1.9 billion (CHF 2.5 billion). A public offer to acquire the outstanding shares from Süd-Chemie minority shareholders will be initiated before the end of May 2011. Süd-Chemie will be fully consolidated as of 21 April 2011.
After closing the acquisition, Clariant started the integration process in order to achieve a quick and seamless integration of the Süd-Chemie businesses into Clariant.
As further steps in the execution of its profitable growth strategy, Clariant has acquired the North American de-icing specialist Octagon Process LLC on 19 March 2011, and the Saskatchewan, Canada-based oil services company Prairie Petro-Chem on 1 April 2011.

Outlook 2011
Starting 2011, Clariant shifted its focus to continuous improvement and profitable growth following the completion of restructuring in 2010. While the continuous improvement initiative “Clariant Excellence” will make the lower cost basis sustainable, the company is now focusing on creating value by investing in future profitable growth.
Clariant expects global economic growth to continue in 2011 but at a slower pace than in 2010. Exchange rates for the major currencies are expected to remain volatile. Growth will mainly come from the emerging markets in Asia/Pacific and Latin America. Commodity prices are expected to continue to rise in 2011, leading to an increase in raw material costs in the mid-teens.
Clariant – excluding the recently acquired Süd-Chemie – expects 2011 sales growth in local currencies in the low single-digit range. Additional benefits from the restructuring measures taken during the last two years will improve the company’s cost position, resulting in a positive impact on the operating result. The EBITDA margin before exceptional items is therefore expected to rise above the 2010 level.

Clariant – Exactly your chemistry.

Clariant is a global leader in the field of specialty chemicals. Strong business relationships, commitment to outstanding service and wide-ranging application know-how make Clariant a preferred partner for its customers.

Clariant, which is represented on five continents with over 100 group companies, employs around 16,200 people. Head-quartered in Muttenz near Basel, Switzerland, it generated sales of CHF 7.1 billion in 2010. Clariant is organized into 10 Business Units: Additives; Detergents & Intermediates; Emulsions; Industrial & Consumer Specialties; Leather Services; Masterbatches; Oil & Mining Services; Paper Specialties; Pigments; and Textile Chemicals.

Clariant is committed to sustainable growth, which is derived from its own innovative strength. Clariant’s world-class products and services play a key role in its customers’ manufacturing processes and add value to their end products. The company’s success is based on the know-how of its people and their ability to identify new customer needs at an early stage and to work together with customers to develop innovative, efficient solutions.

www.clariant.com

EMG
Paulien Boumans
Lelyweg 6
4612 PS
Bergen op Zoom
The Netherlands
0031164317015

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Clariant further expands operating margin here

News-ID: 173905 • Views:

More Releases from Clariant International Ltd

Clariant Innovation Center Cornerstone Laid at Industriepark Höchst for 500 New …
- Finance Minister Thomas Schäfer: Investment brings major benefits - Christian Kohlpaintner: 100 million euros to provide optimal conditions for sustainable, successful research Muttenz / Frankfurt, February 29, 2012 - The cornerstone of the new 100-million-euro Clariant Innovation Center was officially laid during a ceremony today at the Industriepark Höchst in Frankfurt. Attending the event were Hessen State Finance Minister Thomas Schäfer; Clariant Executive Committee member Christian Kohlpaintner; and Ulrich Ott, Managing
Clariant successfully issues EUR 500 million Eurobond
Muttenz, January 17, 2012 – Today, Clariant successfully priced an Eurobond transaction of EUR 500 million with a tenor of 5 years, issued by Clariant Finance (Luxembourg) S.A. and guaranteed by Clariant Ltd. The fixed rate notes with a minimum denomination of EUR 100,000 and a final coupon of 5 ⅝ % p.a. are maturing on January 24, 2017. The orderbook was significantly oversubscribed on the back of strong investor demand.
Clariant’s EasyWhite Tan process — leaner, cleaner and safer
Clariant’s EasyWhite Tan process — leaner, cleaner and safer
Muttenz, November 14, 2011 - Specialty chemicals expert Clariant is offering tanners the first viable scientific and commercial option to traditional tanning methods in some 125 years with the global launch of EasyWhite Tan. The first major advance since the advent of chrome-based tanning revolutionized the industry back in the late 1800s, the new EasyWhite Tan process delivers a ground-breaking alternative to conventional methods based on metals (such as chrome, which
Clariant Strengthens Presence in China with Opening of its First Ethoxylation Pl …
Muttenz/ Shanghai, November 1, 2011 - Clariant, the Swiss leading specialty chemicals company, announced the inauguration of its ethoxylation plant in Daya Bay at Huizhou, Guangdong Province, China today. The plant not only benefits customers with local production but also brings global know-how and technology in product development to the local market. Construction of the plant is pivotal to Clariant’s global strategy on further developing the emerging markets. The plant in

All 5 Releases


More Releases for CHF

Congestive Heart Failure (CHF) Treatment Devices Market Revenue Sizing Outlook A …
Allied Market Research added new research on Global Congestive Heart Failure (CHF) Treatment Devices Market- Global Opportunity Analysis and Industry Forecast, 2022-2030. The Congestive Heart Failure (CHF) Treatment Devices market explores comprehensive study on various segments like size, share, development, innovation, sales and overall growth of major players. The research is based on primary and secondary data sources and it consists both qualitative and quantitative detailing. Some of the key
Chronic Heart Failure (CHF) Drugs Industry Outlook and Forecast 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Chronic Heart Failure (CHF) Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Chronic Heart Failure (CHF) Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global Chronic Heart Failure (CHF) Drugs Market 2020 by Manufacturers, Regions,
Screening Eagle raises CHF 55 million to protect the built world
Screening Eagle Technologies (SET), a cloud-based technology platform connecting sensors, software, and data for intelligent inspection of assets and infrastructure, is pleased to announce it has raised CHF 55 million in its first institutional round of equity funding. Switzerland - April 3, 2020 -- Screening Eagle is on a mission to protect the built world. Massive economic value is at risk from aging global infrastructure and construction birth defects in
Global Congestive Heart Failure (CHF) Market Status, Analysis, Growth Factor, Ap …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Congestive Heart Failure (CHF) Market Research Report 2018” provides an in-depth analysis of the Congestive Heart Failure (CHF) with the forecast of market size and growth. The analysis includes addressable market, market by volume, and market share by business type and by segment (external and in-house).The research study examines the
Congestive Heart Failure (CHF) Treatment Devices Market Latest Trends by 2024
Congestive Heart Failure (CHF) is a chronic condition of a body, which adversely affects the pumping efficiency of the cardiac muscles and the heart. It occurs due to accretion of fluid around the heart that may contribute towards ineffective pumping of the heart. This condition may result in shortness of breathing, swelling and weakness. Left-sided CHF is the more commonly noted than right-sided CHF. Left-sided CHF occurs due to
Congestive Heart Failure (CHF) Treatment Devices Market: Report Scope and Market …
Congestive Heart Failure (CHF) is a chronic condition of a body, which adversely affects the pumping efficiency of the cardiac muscles and the heart. It occurs due to accretion of fluid around the heart that may contribute towards ineffective pumping of the heart. This condition may result in shortness of breathing, swelling and weakness. Left-sided CHF is the more commonly noted than right-sided CHF. Left-sided CHF occurs due to